Fatty liver biomarkers are the quiet section of a routine blood draw and they are also the section most likely to catch metabolic liver disease years before any scan would, because the disease is silent until it is advanced and the markers move early. This guide walks through which markers flag fatty liver on a routine panel, why the standard annual blood work misses the trend and how a quarterly audit reads the trajectory while there is still time to change it.
- Fatty liver disease is silent until advanced, which makes the panel the earliest practical warning system.
- ALT, AST, platelets, fasting insulin, triglycerides and hs-CRP together flag the metabolic liver picture.
- FIB-4 turns routine markers into a fibrosis risk estimate without a scan.
- Weight loss on a branded GLP-1 is among the strongest evidence-backed interventions for the condition.
- Four audits a year inside a flat $299 monthly fee catch the trend on the cadence it actually moves.
Why the panel is the earliest warning system
Metabolic dysfunction-associated steatotic liver disease, the condition formerly called fatty liver disease, affects roughly a quarter of adults by most estimates and produces no symptoms until it is advanced. The liver has no pain signal for fat accumulation and fibrosis develops silently over years. The NIH's NIDDK summary of the condition describes exactly this silence and recommends the risk-based screening that a comprehensive quarterly panel delivers as a byproduct rather than as an event.
The practical consequence is that the blood draw is the earliest warning system most patients will ever get. A scan ordered on suspicion finds the disease later than a panel that was watching the trend.
What the markers say and when
ALT and AST. The liver enzymes, often the first to drift. Mild elevations in the 30 to 80 range are the pattern fatty liver produces for years before anything dramatic appears and a clinician reading population ranges will call them fine while the trend says otherwise.
Platelets. The quiet one. Falling platelets can reflect early fibrosis before enzymes flag anything and they are on every CBC that a standard panel already runs, which makes the omission of the trend reading rather than the marker itself the failure.
Fasting insulin and triglycerides. The metabolic context that drives the condition. Fatty liver is the hepatic expression of insulin resistance and the markers that track insulin resistance track the liver with it.
hs-CRP. The inflammation readout that rises alongside the metabolic picture and gives the panel a cardiovascular cross-read in the same draw.
FIB-4. A calculation from age, AST, platelets and ALT that estimates fibrosis risk from routine markers, which is how a quarterly audit flags who actually needs imaging and who does not.
The fatty liver lane of the audit
| Marker | What it flags | Why standard blood work misses it |
|---|---|---|
| ALT and AST | Early enzyme drift | Read once a year against broad ranges |
| Platelets | Early fibrosis signal | Printed on the CBC and rarely trended |
| Fasting insulin | The driver, insulin resistance | Rarely ordered at all |
| Triglycerides | The metabolic context | Read alone rather than as a system |
| hs-CRP | The inflammation picture | Not part of routine screens |
| FIB-4 | Fibrosis risk from routine markers | Almost never calculated |
What actually moves the markers
The evidence-backed intervention for fatty liver disease is weight loss and the trial literature on branded GLP-1 therapy has moved it from a lifestyle aspiration to a measured clinical lever. Semaglutide showed an average of roughly 15 percent body weight loss in STEP-1 and tirzepatide showed up to about 22.5 percent in SURMOUNT-1 and trials in the fatty liver population specifically have shown enzyme and imaging improvements at magnitudes lifestyle-only programs rarely reach. Individual results vary and no result is promised, but the mechanism is direct: the liver fat that drives the enzymes falls with the weight that carries it.
Our clinical protocols read the fatty liver lane of every quarterly audit and treat the weight and the liver as one system, because they are. Where a branded GLP-1 is clinically indicated, the medication is billed by the pharmacy at its own price with zero markup and no dose escalation fee and the fee for the doctor stays flat at $299 a month with a two month commitment at the start paid as a single $598 charge covering the first two months together.
What is my FIB-4 and what is my ALT trend over the last two years? If nobody can answer, nobody is watching the trajectory.


Cadence, again
The markers in this lane move on a scale of months and the annual draw reads them once a year. Four audits a year catch the trend on the cadence it actually moves, which is the difference between a warning and a finding. Clinical care is delivered by physicians of Beluga Health, P.A., an independent Florida professional corporation licensed in all 50 states, working under GoodLife Health's clinical protocols. All labs run through the Beluga Health lab network and additional labs beyond the quarterly cadence are billed at pass-through cost.
Who gets screened and when
Because the condition is silent, screening is decided by risk rather than by symptoms. The patients who belong in the fatty liver lane of a quarterly audit are the ones carrying any of the standard risk profile: overweight or obesity centered at the waist, type 2 diabetes or prediabetes, elevated triglycerides on any prior draw, high blood pressure or a metabolic picture that includes insulin resistance. Age pushes the risk up steadily past forty and a family history of cirrhosis or liver disease moves the whole conversation earlier.
The screening logic inverts the usual order. Most patients wait for a symptom and none arrives, then meet the disease at a scan ordered for something else or at an advanced stage. The audit approach reverses that: the markers run every quarter as a byproduct of the cardiometabolic panel, the trend gets read every quarter by the clinician who holds the protocol and imaging enters the picture only when FIB-4 or the trend says it should. That is screening as a system rather than screening as an event and it is the only version that catches a silent disease reliably.
The alcohol question, answered honestly
Every fatty liver conversation eventually reaches alcohol and the honest version deserves space. Metabolic dysfunction-associated steatotic liver disease is defined partly by low alcohol intake, which distinguishes it from alcohol-associated liver disease, but the boundary is not a license. Alcohol adds a hepatic injury burden on top of the metabolic one and a patient managing fatty liver markers drinks less rather than more as a general clinical rule, with the specific threshold a conversation with the clinician who reads the panel rather than a number printed in an article.
The reason this section exists in a metabolic article is that patients often arrive with the assumption that abnormal liver markers mean alcohol and therefore carry a private shame about them. In the modern epidemiology the opposite is true. The metabolic driver dominates, insulin resistance and visceral fat explain most of what the enzymes are doing and the shame response is one more reason the markers go undiscussed. The panel does not judge. It measures.
FAQ
What blood tests detect fatty liver? ALT and AST, platelets, fasting insulin, triglycerides and hs-CRP together flag the metabolic liver picture and FIB-4 turns those routine markers into a fibrosis risk estimate.
Can fatty liver show up with normal liver enzymes? Yes, which is why the trend reading matters more than any single draw. Platelets, insulin and triglycerides flag the picture alongside the enzymes.
What is FIB-4? A calculation from age, AST, platelets and ALT that estimates liver fibrosis risk from routine blood markers, used to decide who needs imaging and who does not.
Does weight loss reverse fatty liver? Meaningful weight loss improves liver fat and enzymes and branded GLP-1 trials have shown enzyme and imaging improvements in the fatty liver population. Individual results vary and the quarterly audit is what proves whether the markers moved.
How often should liver markers be checked? Quarterly is the cadence our audit runs on, because the markers move on a scale of months and an annual draw reads that movement once a year.
Does the membership fee include the liver markers? Yes. The quarterly Biomarker Audit reads the full cardiometabolic picture, including the liver-relevant markers, inside the flat $299 monthly fee.
Related Guides
- Cardiometabolic optimization: the definitive guide
- What a Biomarker Audit includes
- Biomarker audit vs annual physical: what you actually get
- Medical weight loss at GoodLife Health
References
- NIH NIDDK: Nonalcoholic fatty liver disease (NAFLD), NASH. 2026. www.niddk.nih.gov/health-information/liver-disease/nafld-nash
- STEP-1: Once-Weekly Semaglutide in Adults with Overweight or Obesity, NEJM 2021. 2021. pubmed.ncbi.nlm.nih.gov/33567185/
- SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity, NEJM 2022. 2022. pubmed.ncbi.nlm.nih.gov/35658024/